转移性去势抵抗性前列腺癌：累积化疗的益处 - Suppr | 超能文献

Metastatic Castration-resistant Prostate Cancer: Piling Up the Benefits of Chemotherapy.

作者信息

Tombal Bertrand

机构信息

Service d'Urologie, Institut de Recherche Clinique, Cliniques universitaires Saint Luc, Brussels, Belgium.

出版信息

Eur Urol. 2015 Aug;68(2):236-7. doi: 10.1016/j.eururo.2014.05.030. Epub 2014 Jun 5.

DOI:10.1016/j.eururo.2014.05.030

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Metastatic Castration-resistant Prostate Cancer: Piling Up the Benefits of Chemotherapy.转移性去势抵抗性前列腺癌：累积化疗的益处

Eur Urol. 2015 Aug;68(2):236-7. doi: 10.1016/j.eururo.2014.05.030. Epub 2014 Jun 5.

2

Re: Nader Al Nakouzi, Sylvestre Le Moulec, Laurence Albigès, et al. Cabazitaxel remains active in patients progressing after docetaxel followed by novel androgen receptor pathway targeted therapies. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2014.04.015.回复：纳迪尔·纳库齐、西尔维斯特·勒穆莱克、劳伦斯·阿尔比热斯等。在多西他赛治疗后进展且随后接受新型雄激素受体途径靶向治疗的患者中，卡巴他赛仍具有活性。《欧洲泌尿外科杂志》。即将发表。http://dx.doi.org/10.1016/j.eururo.2014.04.015 。

Eur Urol. 2014 Oct;66(4):e71-2. doi: 10.1016/j.eururo.2014.06.038. Epub 2014 Jul 8.

3

Serum testosterone level as possible predictive marker in androgen receptor axis-targeting agents and taxane chemotherapies for castration-resistant prostate cancer.血清睾酮水平作为雄激素受体轴靶向药物和紫杉烷类化疗药物治疗去势抵抗性前列腺癌的可能预测标志物。

Urol Oncol. 2019 Mar;37(3):180.e19-180.e24. doi: 10.1016/j.urolonc.2018.10.020. Epub 2018 Nov 13.

4

First-line management of metastatic castrate-resistant prostate cancer patients: Audit of real-life practices.转移性去势抵抗性前列腺癌患者的一线管理：现实实践审计

Bull Cancer. 2017 Jun;104(6):552-558. doi: 10.1016/j.bulcan.2017.02.002. Epub 2017 Apr 5.

5

Real-world outcomes in patients with metastatic castration-resistant prostate cancer receiving second-line chemotherapy versus an alternative androgen receptor-targeted agent (ARTA) following early progression on a first-line ARTA in a US community oncology setting.在美国社区肿瘤学环境中，转移性去势抵抗性前列腺癌患者在一线雄激素受体靶向药物（ARTA）早期进展后接受二线化疗与接受另一种ARTA的真实世界结局。

Urol Oncol. 2018 Nov;36(11):500.e1-500.e9. doi: 10.1016/j.urolonc.2018.08.002. Epub 2018 Sep 7.

6

Do we need new trials for the abiraterone, enzalutamide and cabazitaxel in metastatic castrate-resistant prostate cancer for confirmation of treatment indications?对于阿比特龙、恩杂鲁胺和卡巴他赛用于转移性去势抵抗性前列腺癌的治疗，我们是否需要开展新的试验来确认其治疗适应症？

World J Urol. 2017 Mar;35(3):479-480. doi: 10.1007/s00345-016-1895-2. Epub 2016 Jul 14.

7

Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.治疗转移性去势抵抗性前列腺癌患者：现有疗法的全面综述

J Urol. 2015 Dec;194(6):1537-47. doi: 10.1016/j.juro.2015.06.106. Epub 2015 Jul 18.

8

Third-line Enzalutamide Following Docetaxel and Abiraterone in Metastatic Castrate-resistant Prostate Cancer.多西他赛和阿比特龙治疗后使用恩杂鲁胺作为转移性去势抵抗性前列腺癌的三线治疗

Anticancer Res. 2016 Apr;36(4):1799-803.

9

Activity of cabazitaxel in patients with metastatic castration-resistant prostate cancer after treatment with single or dual regimens of novel androgen receptor-targeting agents.新型雄激素受体靶向药物单药或双药治疗后转移性去势抵抗性前列腺癌患者卡巴他赛的活性。

Med Oncol. 2017 Aug 17;34(9):163. doi: 10.1007/s12032-017-1024-0.

10

Towards random sequencing or precision medicine in castration-resistant prostate cancer?去势抵抗性前列腺癌是走向随机测序还是精准医学？

Eur Urol. 2014 Jan;65(1):37-8. doi: 10.1016/j.eururo.2013.09.019. Epub 2013 Sep 19.

引用本文的文献

1

The presence of intraductal carcinoma of the prostate is closely associated with poor prognosis: a systematic review and meta-analysis.前列腺管内癌的存在与不良预后密切相关：系统评价和荟萃分析。

Asian J Androl. 2021 Jan-Feb;23(1):103-108. doi: 10.4103/aja.aja_21_20.

2

The presence of intraductal carcinoma of the prostate in needle biopsy is a significant prognostic factor for prostate cancer patients with distant metastasis at initial presentation.前列腺内导管癌在前列腺穿刺活检中的存在是初诊时发生远处转移的前列腺癌患者的一个重要预后因素。

Mod Pathol. 2016 Feb;29(2):166-73. doi: 10.1038/modpathol.2015.146. Epub 2016 Jan 8.